Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

Vaccine

Volumn 29, Issue 19, 2011, Pages 3548-3557

  Meier, Sara ^a   Bel, Michael ^a   L'Huillier, Arnaud ^a   Crisinel, Pierre Alex ^a   Combescure, Christophe ^a   Kaiser, Laurent ^a   Grillet, Stéphane ^a   Pósfay Barbe, Klara ^a   Siegrist, Claire Anne ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Children; Chronic diseases; Immunity; Immunization; Influenza

Indexed keywords

AS03 ANTIGEN; INFLUENZA VACCINE; MIFAMURTIDE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

2009 H1N1 INFLUENZA; ABDOMINAL PAIN; ADJUVANT THERAPY; ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CHILD CARE; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INFECTION CONTROL; INFLUENZA VACCINATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; SQUALENE;

EID: 79954994060     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.094     Document Type: Article

References (32)

1. World Health Organisation. DG statement following the meeting of the Emergency Committee. 2009 19.4.2010], Available from: http://www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.html.
2. Swiss Federal Committee for Vaccinations. Recommendations on the vaccination against Influenza A H1N1/09 as of August 13th 2009 (document in French). 2009 3.5.2010]; Available from: http://www.bag.admin.ch/ekif/04423/04429/index.html%3Flang=fr%26download=NHzLpZeg7t,lnp6I0NTU042l2Z6ln1ae2IZn4Z2qZpnO2Yuq2Z6gpJCHe4N5fWym162epYbg2c_JjKbNoKSn6A--
3. Swiss Federal Office of Public Health. Overview of H1N1 Vaccines (document in French). 2009 4.5.2010]; Available from: http://www.bag.admin.ch/influenza/01120/01134/index.html%3Flang=fr%26download=NHzLpZeg7t,lnJ6IzdeIp96km56VmmRqn5ZOqdayYLGH4crdzYam3aiFfm2svWym162epYbg2c_JjKbNoKOn6A--
4. European Medicines Agency. Pandemrix. Summary of product characteristics, approved by the European Commission on the 8th February 2010. 2010 [cited 2010 27.8.2010], Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/05/WC500091295.pdf.
5. European Medicines Agency, Focetria. Summary of product characteristics, approved by the European Commission on the 8th February 2010. 2010.
6. Swissmedic. Swissmedic grants authorisations for pandemic flu vaccines. 30. October 2009. 2009 4.5.2010], Available from: http://www.swissmedic.ch/aktuell/00003/01111/index.html?lang=en.
7. Kessler N., Thomas-Roche G., Gerentes L., Aymard M. Suitability of MDCK cells grown in a serum-free medium for influenza virus production. Dev Biol Stand 1999, 98:13-21. discussion 73-4.
8. Kendal A.P., Pereira M.S., Skehel J.J. Concepts and Procedures for Laboratory-Based Influenza Surveillance 1982, U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, Georgia.
9. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
10. Ikram H., Prince A.M. A method for coupling cytomegalovirus antigens to aldehyde-fixed erythrocytes for use in passive hemagglutination. J Virol Methods 1983, 7(3):127-134.
11. Hosaka Y., Hosokawa Y. Purification of Sendai virions with glutaraldehyde-treated red blood cells. Intervirology 1977, 8(1):1-17.
12. Harmon M.W., Rota P.A., Walls H.H., Kendal A.P. Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection. J Clin Microbiol 1988, 26(2):333-337.
13. Miller E., Hoschler K., Hardelid P., Stanford E., Andrews N., Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010, 375(9720):1100-1108.
14. Wright P.F., Ross K.B., Thompson J., Karzon D.T. Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N Engl J Med 1977, 296(15):829-834.
15. Johnson P.R., Feldman S., Thompson J.M., Mahoney J.D., Wright P.F. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986, 154(1):121-127.
16. Greenbaum J.A., Kotturi M.F., Kim Y., Oseroff C., Vaughan K., Salimi N., et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009, 106(48):20365-20370.
17. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
18. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(9708):41-48.
19. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
20. National Institute of Allergy and Infectious Disease Youngest Children, a Second Dose of 2009 H1N1 Influenza Vaccine Elicits Robust Immune Response 2009, November 02, 2009 [cited 2010 8.8.2010]; Available from: http://www.niaid.nih.gov/news/newsreleases/2009/pages/interimpedsdata.aspx.
21. Carmona A., Omenaca F., Tejedor J.C., Merino J.M., Vaman T., Dieussaert I., et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010.
22. Ansaldi F., Zancolli M., Durando P., Montomoli E., Sticchi L., Del Giudice G., et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010, 28(25):4123-4129.
23. Blumberg E.A., Albano C., Pruett T., Isaacs R., Fitzpatrick J., Bergin J., et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996, 22(2):295-302.
24. Burbach G., Bienzle U., Stark K., Rayes N., Neuhaus R., Serke S., et al. Influenza vaccination in liver transplant recipients. Transplantation 1999, 67(5):753-755.
25. Bate J., Yung C.F., Hoschler K., Sheasby L., Morden J., Taj M., et al. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin Infect Dis 2010, 51(12):e95-e105.
26. Esposito S., Meregalli E., Daleno C., Ghio L., Tagliabue C., Valzano A., et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2010.
27. Manuel O., Humar A., Chen M.H., Chernenko S., Singer L.G., Cobos I., et al. Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant 2007, 7(11):2567-2572.
28. Tanzi E., Amendola A., Pariani E., Zappa A., Colzani D., Logias F., et al. Lack of effect of a booster dose of influenza vaccine in hemodialysis patients. J Med Virol 2007, 79(8):1176-1179.
29. Holvast A., van Assen S., de Haan A., Huckriede A., Benne C.A., Westra J., et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology (Oxford) 2009, 48(10):1294-1299.
30. Swiss Federal Office of Public Health. Influenza Surveillance - Declarations of Suspected Influenza Cases. 2010 10th of August 2010 [cited 2010 16th August 2010]; Available from: http://www.bag.admin.ch/k_m_meldesystem/00736/00816/index.html%3Flang=fr.
31. Zimmer S.M., Crevar C.J., Carter D.M., Stark J.H., Giles B.M., Zimmerman R.K., et al. Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS One 2010, 5(7):pe11601.
32. Weekly epidemiological record, W., Seroepidemiological studies of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec, 2010. 85 (24): p. 229-35.